ERBB2 and breast cancer: Even though there are discrepancies between studies, including the definition of the optimal threshold, the majority suggest that serum HER2ECD might be particularly useful in metastatic BC as an indicator of cancer progression and predictor for anti-HER2 therapies efficacy.